MedTrace Logo

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

NCT04999605 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-01-05

No results posted yet for this study

Summary

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.

Conditions

  • Ovarian Neoplasms
  • Recurrent Ovarian Carcinoma
  • Relapsed Ovarian Cancer
  • Ovarian Cancer

Interventions

DRUG

AK112 low dose

AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor

DRUG

AK112 medium dose

AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor

DRUG

AK112 high dose

AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor

Sponsors & Collaborators

Principal Investigators

  • Lingying Wu, MD · Chinese Academy of Medical Sciences and Peking Union Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-24
Primary Completion
2022-06-10
Completion
2022-06-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999605 on ClinicalTrials.gov